Epigenetic Alteration and MicroRNA Dysregulation in Cancer

Overview

Journal Front Genet

Date 2013 Dec 19

PMID 24348513

Citations 83

Authors

Hiromu Suzuki

Reo Maruyama

Eiichiro Yamamoto

Masahiro Kai

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs) play pivotal roles in numerous biological processes, and their dysregulation is a common feature of human cancer. Thanks to recent advances in the analysis of the cancer epigenome, we now know that epigenetic alterations, including aberrant DNA methylation and histone modifications, are major causes of miRNA dysregulation in cancer. Moreover, the list of miRNA genes silenced in association with CpG island hypermethylation is rapidly growing, and various oncogenic miRNAs are now known to be upregulated via DNA hypomethylation. Histone modifications also play important roles in the dysregulation of miRNAs, and histone deacetylation and gain of repressive histone marks are strongly associated with miRNA gene silencing. Conversely, miRNA dysregulation is causally related to epigenetic alterations in cancer. Thus aberrant methylation of miRNA genes is a potentially useful biomarker for detecting cancer and predicting its outcome. Given that many of the silenced miRNAs appear to act as tumor suppressors through the targeting of oncogenes, re-expression of the miRNAs could be an effective approach to cancer therapy, and unraveling the relationship between epigenetic alteration and miRNA dysregulation may lead to the discovery of new therapeutic targets.

Citing Articles

MicroRNA155 in non-small cell lung cancer: a potential therapeutic target.

Wei X, Xiong X, Chen Z, Chen B, Zhang C, Zhang W Front Oncol. 2025; 15:1517995.

PMID: 39963112 PMC: 11830606. DOI: 10.3389/fonc.2025.1517995.

miR-198 targets : implications for oral squamous cell carcinoma pathogenesis.

Kaushik P, Mishra R, Gopal C, Kumar A Front Oncol. 2024; 14:1485802.

PMID: 39697236 PMC: 11652479. DOI: 10.3389/fonc.2024.1485802.

MicroRNA in prostate cancer: from biogenesis to applicative potential.

Luo X, Wen W BMC Urol. 2024; 24(1):244.

PMID: 39506720 PMC: 11539483. DOI: 10.1186/s12894-024-01634-1.

Role of Circulating microRNAs in Liver Disease and HCC: Focus on miR-122.

Colaianni F, Zelli V, Compagnoni C, Miscione M, Rossi M, Vecchiotti D Genes (Basel). 2024; 15(10).

PMID: 39457437 PMC: 11507253. DOI: 10.3390/genes15101313.

MiR-223-3p in Cancer Development and Cancer Drug Resistance: Same Coin, Different Faces.

Barbagallo D, Ponti D, Bassani B, Bruno A, Pulze L, Akkihal S Int J Mol Sci. 2024; 25(15).

PMID: 39125761 PMC: 11311375. DOI: 10.3390/ijms25158191.

References

Gebauer K, Peters I, Dubrowinskaja N, Hennenlotter J, Abbas M, Scherer R . Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma. Br J Cancer. 2013; 108(1):131-8. PMC: 3553529. DOI: 10.1038/bjc.2012.537. View

Calin G, Sevignani C, Dumitru C, Hyslop T, Noch E, Yendamuri S . Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004; 101(9):2999-3004. PMC: 365734. DOI: 10.1073/pnas.0307323101. View

Wong C, Tellam R . MicroRNA-26a targets the histone methyltransferase Enhancer of Zeste homolog 2 during myogenesis. J Biol Chem. 2008; 283(15):9836-43. DOI: 10.1074/jbc.M709614200. View

Kalimutho M, Di Cecilia S, Del Vecchio Blanco G, Roviello F, Sileri P, Cretella M . Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer. Br J Cancer. 2011; 104(11):1770-8. PMC: 3111174. DOI: 10.1038/bjc.2011.82. View

Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H . Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle. 2008; 7(16):2591-600. DOI: 10.4161/cc.7.16.6533. View

Roman-Gomez J, Agirre X, Jimenez-Velasco A, Arqueros V, Vilas-Zornoza A, Rodriguez-Otero P . Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. J Clin Oncol. 2009; 27(8):1316-22. DOI: 10.1200/JCO.2008.19.3441. View

Wang Y, Toh H, Chow P, Chung A, Meyers D, Cole P . MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms. FASEB J. 2012; 26(7):3032-41. PMC: 3382089. DOI: 10.1096/fj.11-201855. View

Braconi C, Huang N, Patel T . MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology. 2010; 51(3):881-90. PMC: 3902044. DOI: 10.1002/hep.23381. View

Suzuki H, Yamamoto E, Nojima M, Kai M, Yamano H, Yoshikawa K . Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. Carcinogenesis. 2010; 31(12):2066-73. DOI: 10.1093/carcin/bgq203. View

10.

Majid S, Dar A, Saini S, Shahryari V, Arora S, Zaman M . miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin Cancer Res. 2012; 19(1):73-84. PMC: 3910324. DOI: 10.1158/1078-0432.CCR-12-2952. View

11.

Wang H, Wu J, Meng X, Ying X, Zuo Y, Liu R . MicroRNA-342 inhibits colorectal cancer cell proliferation and invasion by directly targeting DNA methyltransferase 1. Carcinogenesis. 2011; 32(7):1033-42. DOI: 10.1093/carcin/bgr081. View

12.

Brueckner B, Stresemann C, Kuner R, Mund C, Musch T, Meister M . The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res. 2007; 67(4):1419-23. DOI: 10.1158/0008-5472.CAN-06-4074. View

13.

Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti G, Papotti M . Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res. 2010; 8(9):1207-16. DOI: 10.1158/1541-7786.MCR-10-0052. View

14.

Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R . Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell. 2012; 22(4):506-523. PMC: 3973134. DOI: 10.1016/j.ccr.2012.09.003. View

15.

Ando T, Yoshida T, Enomoto S, Asada K, Tatematsu M, Ichinose M . DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int J Cancer. 2009; 124(10):2367-74. DOI: 10.1002/ijc.24219. View

16.

Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y . Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 2008; 68(11):4123-32. DOI: 10.1158/0008-5472.CAN-08-0325. View

17.

Siemens H, Neumann J, Jackstadt R, Mansmann U, Horst D, Kirchner T . Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and β-catenin predicts distant metastasis of colon cancer. Clin Cancer Res. 2012; 19(3):710-20. DOI: 10.1158/1078-0432.CCR-12-1703. View

18.

Ozsolak F, Poling L, Wang Z, Liu H, Liu X, Roeder R . Chromatin structure analyses identify miRNA promoters. Genes Dev. 2008; 22(22):3172-83. PMC: 2593607. DOI: 10.1101/gad.1706508. View

19.

Davalos V, Moutinho C, Villanueva A, Boque R, Silva P, Carneiro F . Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene. 2011; 31(16):2062-74. PMC: 3330264. DOI: 10.1038/onc.2011.383. View

20.

Vogt M, Munding J, Gruner M, Liffers S, Verdoodt B, Hauk J . Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch. 2011; 458(3):313-22. DOI: 10.1007/s00428-010-1030-5. View